Wegovy side effects: what the label reports
The short answer
The most common Wegovy side effects in adults on the 2.4 mg injection were nausea (44%, against 16% on placebo), diarrhea (30%), vomiting (24%), constipation (24%), abdominal pain (20%) and headache (14%). Those figures come from three placebo-controlled trials in adults with obesity or overweight, treated for up to 68 weeks. Tell your prescriber about persistent or severe abdominal pain, or anything that could leave you dehydrated.
Key takeaways
- Nausea, diarrhea, vomiting and constipation lead the table for adults on the Wegovy 2.4 mg injection.
- Stomach and bowel reactions were most frequently reported while the dose was being raised.
- Wegovy carries a boxed warning, the strongest kind the FDA requires, about thyroid C-cell tumors.
- It must not be used with a personal or family history of medullary thyroid carcinoma or with MEN 2.
- Report persistent or severe abdominal pain, dehydration or signs of a serious allergic reaction, and tell providers before any surgery.
On this page
- What are the most common side effects of Wegovy?
- How common are stomach side effects on Wegovy?
- Are side effects different on 7.2 mg, on the tablets or in teens?
- Does Wegovy cause hair loss?
- What is the boxed warning, and what are the serious side effects?
- How many people stop Wegovy because of side effects?
- When to call your prescriber
- Frequently asked questions
- Sources
How often it was reported in the label's trials
| Reaction | Placebon=1261 | Wegovy injection 2.4 mg once weeklyn=2116 |
|---|---|---|
| Nausea | 16% | 44% |
| Diarrhea | 16% | 30% |
| Vomiting | 6% | 24% |
| Constipation | 11% | 24% |
| Abdominal Pain | 10% | 20% |
| Headache | 10% | 14% |
| Fatigue | 5% | 11% |
| Dyspepsia | 3% | 9% |
| Dizziness | 4% | 8% |
| Abdominal Distension | 5% | 7% |
| Eructation | Not listed | 7% |
| Hypoglycemia in T2DM | 2% | 6% |
| Flatulence | 4% | 6% |
| Gastroenteritis | 4% | 6% |
| Gastroesophageal Reflux Disease | 3% | 5% |
| Gastritis | 1% | 4% |
| Gastroenteritis Viral | 3% | 4% |
| Hair Loss | 1% | 3% |
| Dysesthesia | 1% | 2% |
| Reaction | Placebon=303 | Wegovy injection 2.4 mg once weeklyn=304 | Wegovy injection 7.2 mg once weeklyn=1311 |
|---|---|---|---|
| Nausea | 13% | 35% | 39% |
| Vomiting | 6% | 16% | 22% |
| Dysesthesia | 0% | 6% | 22% |
| Constipation | 8% | 19% | 20% |
| Abdominal pain | 7% | 9% | 12% |
| Fatigue | 5% | 9% | 11% |
| Headache | 7% | 8% | 9% |
| Dizziness | 1% | 5% | 6% |
| Hair loss | 1% | 3% | 6% |
| Flatulence | 2% | 2% | 4% |
| Reaction | Placebon=67 | Wegovy injection 2.4 mg once weeklyn=133 |
|---|---|---|
| Nausea | 18% | 42% |
| Vomiting | 10% | 36% |
| Diarrhea | 19% | 22% |
| Headache | 16% | 17% |
| Abdominal Pain | 6% | 15% |
| Nasopharyngitis | 10% | 12% |
| Dizziness | 3% | 8% |
| Gastroenteritis | 3% | 7% |
| Constipation | 2% | 6% |
| Gastroesophageal Reflux Disease | 2% | 4% |
| Sinusitis | 2% | 4% |
| Urinary tract infection | 2% | 4% |
| Ligament sprain | 2% | 4% |
| Anxiety | 2% | 4% |
| Hair Loss | 0% | 4% |
| Cholelithiasis | 0% | 4% |
| Eructation | 0% | 4% |
| Influenza | 0% | 3% |
| Rash | 0% | 3% |
| Urticaria | 0% | 3% |
Wegovy: Hair loss
In a pool of studies 2, 3, and 4, hair loss was reported in 3.3% of patients treated with WEGOVY 2.4 mg (4% female, 0.9% male) and in 1% of patients treated with placebo (2% female, 0 male).
Wegovy: Hair loss with Wegovy 7.2 mg
In clinical trials with WEGOVY 7.2 mg injection, hair loss was reported in 5.8% of patients treated with WEGOVY 7.2 mg (8.4% female, 0.2% male), 3.3% of patients treated with WEGOVY 2.4 mg (5.4% female, 0 male), and 1.0% of patients on placebo (1.5% female, 0 male).
Wegovy: Gastrointestinal reactions overall
In clinical trials in adults for weight reduction, 73% of WEGOVY injection-treated patients and 47% of patients receiving placebo reported gastrointestinal adverse reactions, including severe reactions that were reported more frequently among patients receiving WEGOVY injection (4.1%) than placebo (0.9%).
Wegovy: Timing of gastrointestinal reactions
These reactions were most frequently reported during dosage escalation.
Wegovy: Discontinuation due to gastrointestinal reactions
Permanent discontinuation of treatment as a result of a gastrointestinal adverse reaction occurred in 4.3% of WEGOVY injection-treated adult patients versus 0.7% of placebo-treated patients.
Wegovy: Dysesthesia (altered skin sensation) with Wegovy 7.2 mg
In clinical trials evaluating patients with and without type 2 diabetes mellitus, WEGOVY 7.2 mg injection dysesthesia was reported at a higher rate in the WEGOVY 7.2 mg injection group (22%), compared to WEGOVY 2.4 mg injection (6%) and placebo (0.3%).
Wegovy: Dysesthesia with Wegovy tablets
In a clinical trial with WEGOVY 25 mg tablets, 5% of WEGOVY-treated patients and no placebo-treated patients reported dysesthesia adverse reactions.
Wegovy: Gallbladder disease
In WEGOVY clinical trials in adults for weight reduction, cholelithiasis was reported by 1.6% of WEGOVY injection-treated patients and 0.7% of placebo-treated patients and by 2.5% of WEGOVY tablet-treated patients and 1% of placebo tablet-treated patients. Cholecystitis was reported by 0.6% of WEGOVY injection-treated adult patients and 0.2% of placebo-treated patients.
Wegovy: Hypoglycemia in patients with type 2 diabetes
In a trial of adult patients with type 2 diabetes and BMI greater than or equal to 27 kg/m2 for weight reduction, clinically significant hypoglycemia (defined as a plasma glucose less than 54 mg/dL) was reported in 6.2% of WEGOVY injection-treated patients versus 2.5% of placebo-treated patients.
Wegovy: Heart rate increase
In weight reduction trials in which adult patients were randomized prior to dose-escalation, more patients treated with WEGOVY, compared with placebo, had maximum changes from baseline at any visit of 10 to 19 bpm (41% versus 34%, respectively) and 20 bpm or more (26% versus 16%, respectively).
Wegovy: Injection site reactions
In clinical trials in adults for weight reduction, 1.4% of WEGOVY-treated patients and 1% of patients receiving placebo experienced injection site reactions (including injection site pruritus, erythema, inflammation, induration, and irritation).
Wegovy: Diabetic retinopathy in patients with type 2 diabetes
In a trial of adult patients with type 2 diabetes and BMI greater than or equal to 27 kg/m2 for weight reduction, retinal disorders were reported by 6.9% of patients treated with WEGOVY injection (semaglutide 2.4 mg), 6.2% of patients treated with semaglutide 1 mg, and 4.2% of patients treated with placebo.
Wegovy: Acute pancreatitis
In WEGOVY clinical trials in adults for weight reduction, acute pancreatitis was confirmed by adjudication in 4 WEGOVY-treated patients (0.2 cases per 100 patient years) and 1 in placebo-treated patients (less than 0.1 cases per 100 patient years).
Wegovy: Acute kidney injury
Acute kidney injury occurred in clinical trials for weight reduction in 7 adult patients (0.4 cases per 100 patient years) receiving WEGOVY versus 4 patients (0.2 cases per 100 patient years of exposure) receiving placebo.
Wegovy: Low blood pressure and fainting
Adverse reactions related to hypotension (hypotension, orthostatic hypotension, and decreased blood pressure) were reported in 1.3% of WEGOVY-treated adult patients versus 0.4% of placebo-treated patients and syncope was reported in 0.8% of WEGOVY-treated patients versus 0.2% of placebo-treated patients in clinical trials for weight reduction.
Wegovy: Appendicitis
Appendicitis (including perforated appendicitis) occurred in 10 (0.5%) WEGOVY-treated adult patients and 2 (0.2%) patients receiving placebo in clinical trials for weight reduction.
Wegovy: Taste changes (dysgeusia)
In clinical trials in adults for weight reduction, 1.7% of WEGOVY-treated patients and 0.5% of placebo-treated patients reported dysgeusia.
Wegovy: Hip and pelvis fractures
In the CV outcomes trial in adults, more fractures of the hip and pelvis were reported on WEGOVY than on placebo in female patients: 1% (24/2,448) vs. 0.2% (5/2,424), and in patients ages 75 years and older: 2.4% (17/703) vs. 0.6% (4/663), respectively.
Wegovy: Kidney stones (urolithiasis)
In a CV outcomes trial, 1.2% of WEGOVY-treated patients and 0.8% of patients receiving placebo reported urolithiasis, including serious reactions that were reported more frequently among patients receiving WEGOVY (0.6%) than placebo (0.4%).
Wegovy: Amylase and lipase increases
Adult and pediatric patients treated with WEGOVY had a mean increase from baseline in amylase of 15% to 16% and lipase of 39% in clinical trials for weight reduction.
Wegovy: Common reactions with Wegovy tablets
In the clinical trial with WEGOVY 25 mg tablets, the types and frequency of common adverse reactions were similar to those listed in Table 3.
Wegovy: Discontinuation with Wegovy tablets
In the clinical trial, 6.9% of patients treated with WEGOVY 25 mg tablets and 5.9% patients treated with placebo permanently discontinued treatment as a result of adverse reactions.
Wegovy: Discontinuation with Wegovy 7.2 mg
In these clinical trials, 5% of patients treated with 7.2 mg WEGOVY injection, 5% of patients treated with 2.4 mg of WEGOVY injection and 2% of patients treated with placebo permanently discontinued treatment as a result of adverse reactions.
Wegovy: Discontinuation in the cardiovascular outcomes trial
Sixteen percent (16%) of WEGOVY injection-treated patients and 8% of placebo-treated patients, respectively, discontinued study drug due to an adverse event.
Warnings on the Wegovy label
Risk of Thyroid C-Cell Tumors
Semaglutide caused thyroid C-cell tumors in rodents; whether it does in humans is unknown, and Wegovy is contraindicated with a personal or family history of MTC or with MEN 2.
It is unknown whether WEGOVY causes thyroid C-cell tumors, including MTC, in humans, as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
Acute Pancreatitis
Acute pancreatitis, including fatal cases, has been seen with GLP-1 receptor agonists including Wegovy; stop the drug if pancreatitis is suspected.
After initiation of WEGOVY, observe patients carefully for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain (sometimes radiating to the back), and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue WEGOVY and initiate appropriate management.
Acute Gallbladder Disease
Wegovy is associated with more gallstones and gallbladder inflammation, with higher rates in pediatric patients than in adults.
Treatment with WEGOVY is associated with an increased occurrence of cholelithiasis and cholecystitis. The incidence of cholelithiasis and cholecystitis was higher in WEGOVY injection-treated pediatric patients aged 12 years and older than in WEGOVY injection-treated adults.
Hypoglycemia
Wegovy lowers blood glucose and can cause low blood sugar, with a higher risk when used with insulin or a sulfonylurea.
WEGOVY lowers blood glucose and can cause hypoglycemia.
Acute Kidney Injury Due to Volume Depletion
Acute kidney injury, sometimes needing dialysis, has been reported, mostly in people dehydrated by nausea, vomiting or diarrhea.
Monitor renal function in patients reporting adverse reactions to WEGOVY that could lead to volume depletion, especially during dosage initiation and escalation of WEGOVY.
Severe Gastrointestinal Adverse Reactions
Severe gastrointestinal reactions were reported in 4.1% of Wegovy injection patients versus 0.9% on placebo, and Wegovy is not recommended in severe gastroparesis.
Severe gastrointestinal adverse reactions were reported in 4.1% and 0.9% of WEGOVY injection and placebo-treated patients, respectively, and in 2% of WEGOVY tablet-treated and 0% of placebo-treated patients, respectively.
Hypersensitivity Reactions
Serious allergic reactions such as anaphylaxis and angioedema have been reported; stop Wegovy if one occurs.
Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with WEGOVY. If hypersensitivity reactions occur, discontinue use of WEGOVY, treat promptly per standard of care, and monitor until signs and symptoms resolve.
Diabetic Retinopathy Complications in Patients with Type 2 Diabetes
In a 2-year trial of semaglutide injection in type 2 diabetes, diabetic retinopathy complications occurred in 3% versus 1.8% on placebo; patients with a history of retinopathy should be monitored.
In a 2-year trial with semaglutide 0.5 mg and 1 mg once-weekly injection in adult patients with type 2 diabetes and high CV risk, diabetic retinopathy complications (which was a 4-component adjudicated endpoint) occurred in patients treated with semaglutide injection (3%) compared to placebo (1.8%).
Heart Rate Increase
Wegovy raised resting heart rate by a mean of 1 to 4 beats per minute versus placebo in adult weight-reduction trials.
Treatment with WEGOVY was associated with increases in resting heart rate. Mean increases in resting heart rate of 1 to 4 beats per minute (bpm) were observed in WEGOVY injection-treated adult patients compared to placebo in clinical trials for weight reduction.
Pulmonary Aspiration During General Anesthesia or Deep Sedation
Because Wegovy slows stomach emptying, rare cases of aspiration during anesthesia or deep sedation have been reported with GLP-1 receptor agonists; tell providers before planned procedures.
Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking WEGOVY.
Never Share WEGOVY FlexTouch Between Patients
The multi-dose Wegovy FlexTouch pen must never be shared, even with a new needle, because of infection risk.
WEGOVY FlexTouch must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens.
If a side effect has you worried, tell your prescriber about persistent or severe abdominal pain, and about nausea, vomiting or diarrhea that could leave you dehydrated. Report signs of a serious allergic reaction too. Leave dose decisions to your prescriber.
Wegovy comes as a weekly injection and a daily tablet, and its label reports side effects in several separate groups: adults on the 2.4 mg injection, adults on the 7.2 mg injection, adolescents, and adults on the 25 mg tablet. The tables on this page show each group in full. This guide explains how they differ.
What are the most common side effects of Wegovy?
The main table covers three placebo-controlled trials in adults with obesity or overweight, treated with the 2.4 mg injection for up to 68 weeks. A placebo group gets an inactive treatment instead of the medicine. Here’s the share of patients reporting each reaction, with placebo second:
- Nausea: 44% and 16%.
- Diarrhea: 30% and 16%.
- Vomiting: 24% and 6%.
- Constipation: 24% and 11%.
- Abdominal pain: 20% and 10%.
- Headache: 14% and 10%.
- Fatigue: 11% and 5%.
- Dyspepsia (indigestion): 9% and 3%.
Injection site reactions such as itching and redness were reported by 1.4% of Wegovy patients and 1% on placebo.
How common are stomach side effects on Wegovy?
Very common. In the adult weight reduction trials, 73% of patients on the Wegovy injection reported a gastrointestinal (stomach or bowel) reaction, against 47% on placebo. The label says these reactions “were most frequently reported during dosage escalation,” the weeks when the dose is being raised.
Severe gastrointestinal reactions were reported by 4.1% of Wegovy injection patients and 0.9% on placebo, and by 2% of Wegovy tablet patients and 0% on placebo. The label doesn’t recommend Wegovy in people with severe gastroparesis (a stomach that empties very slowly).
Are side effects different on 7.2 mg, on the tablets or in teens?
Wegovy 7.2 mg. Two 72-week trials in adults with obesity compared 7.2 mg with 2.4 mg and placebo. Nausea was reported by 39%, 35% and 13%, and vomiting by 22%, 16% and 6%. The reaction that separates the doses is dysesthesia, an altered skin sensation: 22% on 7.2 mg, 6% on 2.4 mg and 0.3% on placebo.
Wegovy tablets. The label says the types and frequency of common reactions in the 25 mg tablet trial “were similar to those listed in Table 3,” the 2.4 mg injection table. Dysesthesia was reported by 5% of tablet patients and no placebo patients.
Adolescents aged 12 and older. In a 68-week trial, nausea was reported by 42% on Wegovy and 18% on placebo, vomiting by 36% and 10%, and diarrhea by 22% and 19%. Gallstones were reported by 4% on Wegovy and 0% on placebo, and the label says gallbladder problems were more frequent in adolescents than in adults.
Does Wegovy cause hair loss?
It’s in the table: 3% on Wegovy 2.4 mg and 1% on placebo. Women reported it more than men (4% against 0.9%). At 7.2 mg the figure was 5.8%, and 8.4% among women. The hair loss page compares the labels.
What is the boxed warning, and what are the serious side effects?
Wegovy carries a boxed warning for thyroid C-cell tumors. A boxed warning is the strongest kind the FDA requires, set apart in a box on the label. Semaglutide causes these tumors in rodents, and the label says it’s unknown whether Wegovy causes them, “including medullary thyroid carcinoma (MTC), in humans.” Wegovy is contraindicated, meaning it must not be used, with a personal or family history of MTC or with MEN 2 (Multiple Endocrine Neoplasia syndrome type 2).
Other warnings, with the label’s figures:
- Acute pancreatitis (inflammation of the pancreas): confirmed in 4 Wegovy patients and 1 placebo patient in the adult trials.
- Gallbladder disease: gallstones in 1.6% on the Wegovy injection and 0.7% on placebo.
- Low blood sugar: in adults with type 2 diabetes, 6.2% on Wegovy and 2.5% on placebo had glucose below 54 mg/dL.
- Acute kidney injury, mostly in people dehydrated by nausea, vomiting or diarrhea.
- Serious allergic reactions, including anaphylaxis, a sudden and severe whole-body reaction, and angioedema, swelling under the skin.
- Heart rate: a mean rise of 1 to 4 beats per minute against placebo.
- Diabetic retinopathy (eye damage from diabetes), pulmonary aspiration (stomach contents entering the lungs), and a warning never to share a Wegovy FlexTouch pen.
In the cardiovascular outcomes trial, hip and pelvis fractures were reported more often on Wegovy than placebo in women (1% against 0.2%) and in patients aged 75 and older (2.4% against 0.6%). See the safety guide.
How many people stop Wegovy because of side effects?
In the 2.4 mg trials, 6.8% of Wegovy patients and 3.2% of placebo patients permanently stopped because of side effects. Nausea led the reasons (1.8% against 0.2%), then vomiting (1.2% against 0%) and diarrhea (0.7% against 0.1%). With the tablets the figures were 6.9% and 5.9%.
When to call your prescriber
The label names specific things to report:
- Persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting. The label lists these as signs of acute pancreatitis.
- Nausea, vomiting or diarrhea that could leave you dehydrated. The label asks prescribers to monitor kidney function in that case.
- Signs of a serious allergic reaction.
- Any planned surgery or procedure. The label tells patients to let their healthcare providers know beforehand that they take Wegovy.
Leave dose decisions to your prescriber. The Wegovy guide covers the rest of the label, and the side effects guide sets each reaction across medicines.
Frequently asked questions
What are the most common side effects of Wegovy?
In adults on the 2.4 mg injection, nausea was reported by 44% of patients, diarrhea by 30%, vomiting by 24%, constipation by 24%, abdominal pain by 20%, headache by 14% and fatigue by 11%. On placebo the same reactions were reported by 16%, 16%, 6%, 11%, 10%, 10% and 5%. The label says the tablet trial showed similar common reactions.
How long do Wegovy side effects last?
The label says stomach and bowel reactions were most frequently reported during dosage escalation, the weeks when the dose is stepped up. That describes the whole trial group, not what you personally should expect. If a reaction doesn't ease, or it keeps you from eating and drinking, raise it with your prescriber.
Does Wegovy cause hair loss?
Hair loss is in the label's table: 3% of adults on Wegovy 2.4 mg and 1% on placebo. It was reported by 4% of women and 0.9% of men on Wegovy. In the trials of the 7.2 mg dose, hair loss was reported by 5.8% of patients on 7.2 mg, including 8.4% of women.
Is Wegovy safe?
The label doesn't answer with a yes or a no. It carries a boxed warning, the strongest kind the FDA requires: semaglutide causes thyroid C-cell tumors in rodents, and it's unknown whether Wegovy causes them in humans. Wegovy must not be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2. Whether it suits you is a decision for your prescriber.
What are the serious side effects of Wegovy?
The label's warnings cover acute pancreatitis, acute gallbladder disease, low blood sugar, acute kidney injury after dehydration, severe stomach and bowel reactions, serious allergic reactions, diabetic retinopathy complications (eye damage from diabetes), a rise in heart rate and pulmonary aspiration during anesthesia. Severe stomach and bowel reactions were reported by 4.1% of Wegovy injection patients and 0.9% on placebo.
Are side effects worse on Wegovy 7.2 mg?
Some were more frequent. In the two trials of the 7.2 mg dose, nausea was reported by 39% of patients on 7.2 mg and 35% on 2.4 mg, and vomiting by 22% and 16%. Dysesthesia, an altered skin sensation, stood out: 22% on 7.2 mg, 6% on 2.4 mg. The share who stopped treatment was 5% at both doses.
Sources (2)
- 1.FDA label (DailyMed): Wegovy prescribing information, section 4
“a personal or family history of MTC or in patients with MEN 2”
- 2.
Related pages
- What is Wegovy? Uses, doses, pill and pen, and cost
- GLP-1 side effects: what the FDA labels report
- Wegovy cost: pen and pill prices with and without insurance
- Wegovy for heart disease: the approved use, the trial behind it and who pays
- Wegovy for MASH: what is approved, what the trial showed and who covers it
- Does Medicare cover Wegovy?
